These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

84 related items for PubMed ID: 1988093

  • 21. Synergistic antitumor effect of interferon and anti-idiotype monoclonal antibody in murine lymphoma.
    Basham TY, Kaminski MS, Kitamura K, Levy R, Merigan TC.
    J Immunol; 1986 Nov 01; 137(9):3019-24. PubMed ID: 3760580
    [Abstract] [Full Text] [Related]

  • 22. Induction of antibody-dependent cellular cytotoxicity in vivo by IFN-alpha and its antitumor efficacy against established B16 melanoma liver metastases when combined with specific anti-B16 monoclonal antibody.
    Eisenthal A, Cameron RB, Rosenberg SA.
    J Immunol; 1990 Jun 01; 144(11):4463-71. PubMed ID: 2111349
    [Abstract] [Full Text] [Related]

  • 23. Neutrophils contribute to the biological antitumor activity of rituximab in a non-Hodgkin's lymphoma severe combined immunodeficiency mouse model.
    Hernandez-Ilizaliturri FJ, Jupudy V, Ostberg J, Oflazoglu E, Huberman A, Repasky E, Czuczman MS.
    Clin Cancer Res; 2003 Dec 01; 9(16 Pt 1):5866-73. PubMed ID: 14676108
    [Abstract] [Full Text] [Related]

  • 24. Radiotherapy in mice with yttrium-90-labeled anti-Ly1 monoclonal antibody: therapy of the T cell lymphoma EL4.
    Schmidberger H, Buchsbaum DJ, Blazar BR, Everson P, Vallera DA.
    Cancer Res; 1991 Apr 01; 51(7):1883-90. PubMed ID: 2004371
    [Abstract] [Full Text] [Related]

  • 25. Vascular attack by 5,6-dimethylxanthenone-4-acetic acid combined with B7.1 (CD80)-mediated immunotherapy overcomes immune resistance and leads to the eradication of large tumors and multiple tumor foci.
    Kanwar JR, Kanwar RK, Pandey S, Ching LM, Krissansen GW.
    Cancer Res; 2001 Mar 01; 61(5):1948-56. PubMed ID: 11280751
    [Abstract] [Full Text] [Related]

  • 26. Specific targeting of adriamycin conjugates with monoclonal antibodies to hepatoma associated antigens to intrahepatic tumors in athymic mice.
    Adler R, Hurwitz E, Wands JR, Sela M, Shouval D.
    Hepatology; 1995 Nov 01; 22(5):1482-7. PubMed ID: 7590667
    [Abstract] [Full Text] [Related]

  • 27. Divergent effects of 4-1BB antibodies on antitumor immunity and on tumor-reactive T-cell generation.
    Kim JA, Averbook BJ, Chambers K, Rothchild K, Kjaergaard J, Papay R, Shu S.
    Cancer Res; 2001 Mar 01; 61(5):2031-7. PubMed ID: 11280763
    [Abstract] [Full Text] [Related]

  • 28. In vitro and in vivo evaluation of human tumor necrosis factor-alpha (hTNFalpha) chemically conjugated to monoclonal antibody.
    Pietersz GA, Toohey B, McKenzie IF.
    J Drug Target; 1998 Mar 01; 5(2):109-20. PubMed ID: 9588867
    [Abstract] [Full Text] [Related]

  • 29. Cytotoxic effect of anti-Mr 67,000 protein immunotoxins on human tumors in a nude mouse model.
    Weil-Hillman G, Runge W, Jansen FK, Vallera DA.
    Cancer Res; 1985 Mar 01; 45(3):1328-36. PubMed ID: 3971376
    [Abstract] [Full Text] [Related]

  • 30. Identification of a monoclonal antibody, TV-1, directed against the basement membrane of tumor vessels, and its use to enhance the delivery of macromolecules to tumors after conjugation with interleukin 2.
    Epstein AL, Khawli LA, Hornick JL, Taylor CR.
    Cancer Res; 1995 Jun 15; 55(12):2673-80. PubMed ID: 7780984
    [Abstract] [Full Text] [Related]

  • 31. Tumor immunotherapy in the mouse with the use of 131I-labeled monoclonal antibodies.
    Zalcberg JR, Thompson CH, Lichtenstein M, McKenzie IF.
    J Natl Cancer Inst; 1984 Mar 15; 72(3):697-704. PubMed ID: 6583453
    [Abstract] [Full Text] [Related]

  • 32. Antitumor efficacy of a combination of CMC-544 (inotuzumab ozogamicin), a CD22-targeted cytotoxic immunoconjugate of calicheamicin, and rituximab against non-Hodgkin's B-cell lymphoma.
    DiJoseph JF, Dougher MM, Kalyandrug LB, Armellino DC, Boghaert ER, Hamann PR, Moran JK, Damle NK.
    Clin Cancer Res; 2006 Jan 01; 12(1):242-9. PubMed ID: 16397048
    [Abstract] [Full Text] [Related]

  • 33. Targeted therapy of experimental renal cell carcinoma with a novel conjugate of monoclonal antibody 138H11 and calicheamicin thetaI1.
    Knoll K, Wrasidlo W, Scherberich JE, Gaedicke G, Fischer P.
    Cancer Res; 2000 Nov 01; 60(21):6089-94. PubMed ID: 11085532
    [Abstract] [Full Text] [Related]

  • 34. Immunotherapeutic strategies in neuroblastoma: antitumoral activity of deglycosylated Ricin A conjugated anti-GD2 antibodies and anti-CD3xanti-GD2 bispecific antibodies.
    Manzke O, Russello O, Leenen C, Diehl V, Bohlen H, Berthold F.
    Med Pediatr Oncol; 2001 Jan 01; 36(1):185-9. PubMed ID: 11464879
    [Abstract] [Full Text] [Related]

  • 35. Increased antitumor effect of immunoconjugates and tumor necrosis factor in vivo.
    Smyth MJ, Pietersz GA, McKenzie IF.
    Cancer Res; 1988 Jul 01; 48(13):3607-12. PubMed ID: 3259905
    [Abstract] [Full Text] [Related]

  • 36. Differential antigenic expression of the DBA/2 lymphoma L1210 and its sublines: cross-reactivity with C3H mammary tumors as defined by syngeneic monoclonal antibodies.
    Rapp L, Fuji H.
    Cancer Res; 1983 Jun 01; 43(6):2592-9. PubMed ID: 6342755
    [Abstract] [Full Text] [Related]

  • 37. Improved radioimmunotherapeutic efficacy of an anticarcinoma monoclonal antibody (131I-CC49) when given in combination with gamma-interferon.
    Greiner JW, Ullmann CD, Nieroda C, Qi CF, Eggensperger D, Shimada S, Steinberg SM, Schlom J.
    Cancer Res; 1993 Feb 01; 53(3):600-8. PubMed ID: 8425194
    [Abstract] [Full Text] [Related]

  • 38. Anti-B4-blocked ricin immunotoxin shows therapeutic efficacy in four different SCID mouse tumor models.
    Shah SA, Halloran PM, Ferris CA, Levine BA, Bourret LA, Goldmacher VS, Blättler WA.
    Cancer Res; 1993 Mar 15; 53(6):1360-7. PubMed ID: 7680284
    [Abstract] [Full Text] [Related]

  • 39. Potent and specific antitumor efficacy of CMC-544, a CD22-targeted immunoconjugate of calicheamicin, against systemically disseminated B-cell lymphoma.
    DiJoseph JF, Goad ME, Dougher MM, Boghaert ER, Kunz A, Hamann PR, Damle NK.
    Clin Cancer Res; 2004 Dec 15; 10(24):8620-9. PubMed ID: 15623646
    [Abstract] [Full Text] [Related]

  • 40. Anti-T cell-specific immunoconjugates in mice: in vivo effects.
    Mottram PL, Smyth M, Pietersz GA, Clunie GJ, McKenzie IF.
    Transplant Proc; 1989 Oct 15; 21(5):3757-8. PubMed ID: 2573184
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 5.